Acute Deep Vein Thrombosis in the Setting of Tirzepatide Use: A Case Highlighting Emerging Concerns.
Sonavane. Kunal K; Agrawal. Gautam G; Agarwal. Bhawna B; Parsi. Saketh S; Ponnam. Hari Krishna Choudary HKC; Shirsat. Pallavi P
Key Findings
- Tirzepatide is generally well tolerated but may be linked to rare thrombotic events.
- The reported case had an unprovoked deep vein thrombosis shortly after beginning tirzepatide.
- Stopping tirzepatide and initiating anticoagulation resolved symptoms, and extensive clotting workup was negative.
Practical Outcomes
- If you’re using tirzepatide, watch for leg pain, swelling, or other signs of clots, especially in the first few months. Consider discussing clot risk with your clinician and be ready to pause the drug if symptoms appear. This case doesn’t prove a direct cause, but it’s a reminder to stay vigilant about rare but serious side effects.
Summary
A woman who started tirzepatide for weight loss and blood sugar control developed an unexpected deep vein clot a few months later. Tests showed no other clotting problems, and her symptoms got better after stopping the drug and taking blood thinners. This suggests tirzepatide might sometimes increase clot risk, even though it’s not a common side effect.
Abstract
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 agonist, is gaining popularity for its weight reduction, improved glycemic control, and cardiorenal benefits. While it is generally well tolerated, thrombotic events have not been commonly reported. We report a case of a woman who developed an unprovoked deep vein thrombosis within months of starting tirzepatide. An extensive hypercoagulability workup was negative. Her symptoms improved with anticoagulation and discontinuation of tirzepatide. This case highlights a potential risk of thromboembolic events associated with tirzepatide. Clinicians need to be vigilant and exercise extreme caution as the emerging adverse event profile of this novel medication unfolds.
Study Information
pubmed
2025
2025-10-30T00:00:00.000Z
10.1210/jcemcr/luaf248
11